Accoast trial results
May 09, 2016 The ACCOAST trial was a prospective, randomized trial involving 4, 033 patients with a diagnosis of NSTEACS and an elevated troponin level, who were randomized to receive either doubleblind therapy with prasugrel or placebo at 171 centers in 19 countries.Dec 23, 2014 Results The incidence of the primary endpoint through 7 days from randomization in the pretreatment group versus the no pretreatment group was 13. 1 versus 13. 1 (p 0. 93). Pretreatment with prasugrel was not associated with decreases in any ischemic event, including total mortality. Patients with thrombus on angiography had a 3fold higher incidence of the primary endpoint than patients accoast trial results
The ACCOAST (A Comparison of Prasugrel at PCI or Time of Diagnosis of NonST Elevation Myocardial Infarction) trial therefore assessed a strategy of pretreatment with prasugrel in NSTEMI patients, with the result of no ischemic benefit, but an increase in bleeding regardless of the vascularization strategy [13.